Background::Chronic HBV and HDV coinfection represents the most severe form of viral hepatitis. This study aimed to assess the safety and efficacy of libevitug (HH-003), a novel human monoclonal antibody targeting the PreS1 domain of the HBV large envelope protein, in patients with chronic HBV and HDV coinfection.
Methods::This single-center, open-label, proof-of-concept phase IIa clinical trial enrolled 9 participants who received i.v. infusion of 20 mg/kg libevitug every 2 weeks for 24 weeks, followed by a 24-week follow-up period.
Results::
At week 24, 8 participants (88.9%) exhibited a reduction in HDV RNA ≥1 log
10
from baseline, with 4 (44.4%) achieving undetectable levels. 7 participants (77.8%) achieved virological response (undetectable HDV RNA or ≥2 log
10
decline from baseline). Among the 5 participants with elevated baseline ALT, 3 (60.0%) achieved a combined virological and biochemical response (ALT normalization). At week 48, 6 participants (66.7%) maintained the virological response achieved at the end of treatment (week 24), with 3 (33.3%) maintaining undetectable HDV RNA levels. Among the 7 participants with quantifiable HBV DNA at baseline, 2 (28.6%) achieved undetectable HBV DNA or ≥1 log
10
reduction at week 24. Serum HBsAg levels remained unchanged throughout the study period. Treatment-emergent adverse events were reported in 8 participants (88.9%), with only 1 participant (11.1%) experiencing treatment-related adverse events. No grade 3 or serious adverse events were reported, and no discontinuations due to adverse events occurred.
Conclusions::Libevitug demonstrated promising antiviral activity, achieving substantial HDV RNA reduction, a high rate of ALT normalization, and favorable safety and tolerability in participants with chronic HBV and HDV coinfection.